iShares US Pharmaceuticals ETF
101 hedge funds and large institutions have $139M invested in iShares US Pharmaceuticals ETF in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 41 reducing their positions, and 16 closing their positions.
73% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $605K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 108 → 101 (-7)
39.34% less ownership
Funds ownership: 146.12% → 106.78% (-39%)
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
51% less capital invested
Capital invested by funds: $285M → $139M (-$146M)
59% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 41
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$2.98M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.42M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$681K |
| 4 |
SB
Suntrust Banks
Atlanta,
Georgia
|
+$423K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$419K |
Top Sellers
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$116M |
| 2 |
Mawer Investment Management
Calgary,
Alberta, Canada
|
-$8.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.91M |
| 4 |
Jane Street
New York
|
-$3.5M |
| 5 |
AWA
ARS Wealth Advisors
St. Petersburg,
Florida
|
-$2.52M |
IHE Hedge Fund Activity: Q1 2018 in Review
101 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q1 2018, worth a combined $139M — down 51% from $285M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of IHE and 9 opened new positions — a net loss of 7 holders — while 41 trimmed existing stakes and 17 added.
The largest buyer was Morgan Stanley, adding an estimated $2.98M. The largest seller was Clal Insurance, exiting entirely with an estimated $116M sold.
- 101 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q1 2018, down from 108 in Q4 2017.
- Funds reported $139M of iShares US Pharmaceuticals ETF stock for Q1 2018, down 51% quarter-over-quarter.
- 9 funds opened new iShares US Pharmaceuticals ETF positions in Q1 2018 and 16 closed out, a net change of -7 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q1 2018 was Morgan Stanley, an estimated $2.98M added.
- The largest iShares US Pharmaceuticals ETF seller in Q1 2018 was Clal Insurance, an estimated $116M sold.
Based on aggregated 13F filings for Q1 2018.